Inflammatory Myositis
8
3
3
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.5%
1 terminated out of 8 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
Follow-up of Patients With Inflammatory Myopathies Associated With a Biobank
Rare AutoImmune SElf-management Programme Development
ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS
Clinical Database and Biobank of Patients With Inflammatory Myopathies: the MASC Project (Myositis, DNA, Serum, Cells) (MASC)
COVID-19 Vaccination in Rheumatic Disease Patients
Cell Surface Marker Expression in Autoimmune Diseases
Rituximab-induced Pulmonary Function Changes